The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma

Pathology International

Volumn 63, Issue 1, 2013, Pages 37-44

  Akiyama, Kosuke ^a   Ohga, Noritaka ^a   Maishi, Nako ^a   Hida, Yasuhiro ^b   Kitayama, Kazuko ^a   Kawamoto, Taisuke ^a   Osawa, Takahiro ^a   Suzuki, Yuko ^a   Shinohara, Nobuo ^a   Nonomura, Katsuya ^a   Shindoh, Masanobu ^a   Hida, Kyoko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Anti angiogenic drugs; Prostaglandin F2 receptor; Renal cell carcinoma; Tumor endothelial cells

Indexed keywords

CD31 ANTIGEN; PROSTAGLANDIN F RECEPTOR; PROSTAGLANDIN RECEPTOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; RECEPTORS, PROSTAGLANDIN; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84873870857     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12031     Document Type: Article

References (32)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
3. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
4. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591.
5. Kane RC, Farrell AT, Saber H etal. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12: 7271-7278.
6. Pàez-Ribes M, Allen E, Hudock J etal. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
8. Matsuda K, Ohga N, Hida Y etal. Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 2010; 394: 947-954.
9. Ohga N, Hida K, Hida Y etal. Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells. Cancer Sci 2009; 100: 1963-1970.
10. Hida K, Kawamoto T, Ohga N, Akiyama K, Hida Y, Shindoh M. Altered angiogenesis in the tumor microenvironment. Pathol Int 2011; 61: 630-637.
11. Hida K, Hida Y, Amin DN etal. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64: 8249-8255.
12. Akino T, Hida K, Hida Y etal. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009; 175: 2657-2667.
13. Akiyama K, Ohga N, Hida Y etal. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 2012; 180: 1283-1293.
14. McDermott DF, Regan MM, Clark JI etal. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141.
15. Escudier B, Eisen T, Stadler WM etal. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
16. Motzer RJ, Hutson TE, Tomczak P etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
17. Rini BI, Tamaskar I, Shaheen P etal. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-83.
18. Chu TF, Rupnick MA, Kerkela R etal. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
19. Yamamoto K, Ohga N, Hida Y etal. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer 2012; 106: 1214-1223.
20. Maishi N, Ohga N, Hida Y etal. CXCR7: A novel tumor endothelial marker in renal cell carcinoma. Pathol Int 2012; 62: 309-317.
21. Osawa T, Ohga N, Hida Y etal. Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner. Cancer Sci 2012; 103: 1038-1044.
22. Tong BJ, Tan J, Tajeda L etal. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000; 2: 483-490.
23. Sales KJ, Milne SA, Williams AR, Anderson RA, Jabbour HN. Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: Regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. J Clin Endocrinol Metab 2004; 89: 986-993.
24. Jabbour HN, Sales KJ, Boddy SC, Anderson RA, Williams AR. A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. Endocrinology 2005; 146: 4657-4664.
25. Sales KJ, List T, Boddy SC etal. A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res 2005; 65: 7707-7716.
26. Sales KJ, Boddy SC, Williams AR, Anderson RA, Jabbour HN. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 2007; 148: 3635-3644.
27. Keightley MC, Brown P, Jabbour HN, Sales KJ. F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2. BMC Cell Biol 2010; 11: 8.
28. Kurosu T, Ohga N, Hida Y etal. HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 2011; 104: 819-829.
29. Hofer G, Bieglmayer C, Kopp B, Janisch H. Measurement of eicosanoids in menstrual fluid by the combined use of high pressure chromatography and radioimmunoassay. Prostaglandins 1993; 45: 413-426.
30. Smith OP, Battersby S, Sales KJ, Critchley HO, Jabbour HN. Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor Receptor and the extracellular signaling receptor kinase 1/2 pathway. Endocrinology 2006; 147: 1697-1705.
31. Muraki C, Ohga N, Hida Y etal. Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells. Int J Cancer 2012; 130: 59-70.
32. Wang S, Yang Q, Fung K-M etal. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol 2008; 289: 60-66.